



April 15, 2021

2021-SMT-0053

U.S. Nuclear Regulatory Commission
ATTN: Document Control Desk
Washington, DC 20555

References: (1) U.S. Nuclear Regulatory Commission, "SHINE Medical Technologies, LLC – Discussion of Staggered Approach of Construction, Operation, and Licensing," Public Meeting Announcement, April 6, 2021 (ML21096A045)

Meeting Slides from the April 13, 2021 Public Meeting between SHINE Medical Technologies, LLC and the NRC

A meeting was held on April 13, 2021 between SHINE Medical Technologies, LLC (SHINE) and the NRC staff (Reference 1) to discuss the SHINE phased approach to initial facility operations and a request to amend the SHINE construction permit to include authorization for the receipt and possession of certain radioactive material in connection with construction of the facility.

Enclosure 1 provides the non-public version of the SHINE meeting slides for the discussion regarding the SHINE phased approach to initial facility operations. Enclosure 1 contains security-related information which was identified utilizing the guidance contained in Regulatory Issue Summary (RIS) 2005-31. SHINE requests the NRC withhold Enclosure 1 from public disclosure under 10 CFR 2.390.

Enclosure 2 provides the public version of the SHINE meeting slides for the discussion regarding the SHINE phased approach to initial facility operations.

Enclosure 3 provides the non-public version of the SHINE meeting slides for the discussion regarding a request to amend the SHINE construction permit to include authorization for the receipt and possession of certain radioactive material in connection with construction of the facility. Enclosure 3 contains security-related information which was identified utilizing the guidance contained in Regulatory Issue Summary (RIS) 2005-31. SHINE requests the NRC withhold Enclosure 3 from public disclosure under 10 CFR 2.390.

Enclosure 4 provides the public version of the SHINE meeting slides for the discussion regarding a request to amend the SHINE construction permit to include authorization for the receipt and possession of certain radioactive material in connection with construction of the facility.

Enclosures 1 and 3 contain security related information.
Withhold from public disclosure under 10 CFR 2.390.
Upon removal of Enclosures 1 and 3, this letter is uncontrolled.

Document Control Desk
Page 2

If you have any questions, please contact Mr. Jeff Bartelme, Director of Licensing,
at 608/210-1735.

Very truly yours,

DocuSigned by:

F52DB96989224FF...

James Costedio
Vice President of Regulatory Affairs and Quality
SHINE Medical Technologies, LLC
Docket No. 50-608

Enclosures

cc: Project Manager, USNRC
SHINE General Counsel
Supervisor, Radioactive Materials Program, Wisconsin Division of Public Health
(w/o Enclosures 1 and 3)